BOTULINUM TOXIN TYPE A IN THE TREATMENT OF CHRONIC MIGRAINE: CURRENT STATE OF KNOWLEDGE AND THERAPEUTIC PERSPECTIVES
Abstract
Migraine is one of the most common and burdensome neurological disorders, affecting approximately 15% of the global population. This paper provides a review of the current knowledge on the epidemiology, pathophysiology, and treatment of chronic migraine, with particular emphasis on the role of botulinum toxin type A. It presents the key biological mechanisms underlying migraine, including activation of the trigeminovascular system, the significance of neuropeptides such as CGRP, and the involvement of cortical spreading depression (CSD) in migraine with aura. Modern pathophysiological concepts related to autonomic and metabolic system dysfunction are also discussed. Based on an analysis of clinical trials and meta-analyses, the efficacy and safety of onabotulinumtoxinA therapy according to the PREEMPT protocol are evaluated, as well as its place in current therapeutic guidelines. The paper concludes with a discussion of future research perspectives, including the potential for synergy with biological therapies (anti-CGRP), optimization of treatment regimens, and the use of biomarkers.
References
Andrée, C. et al. (2020). Neuromodulation Techniques in Migraine Prevention. Pain, 161(9), 2024-2032. https://doi.org/10.1097/j.pain.0000000000001931
Ann Indian Acad Neurol. (2016). Understanding migraine: potential role of neurogenic inflammation. Annals of Indian Academy of Neurology. https://doi.org/10.4103/aian.AIAN_90_16
Aoki, K. R. (2005). Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology, 26(5), 785-793. https://doi.org/10.1016/j.neuro.2005.06.003
Ashina M, et al. Advances in understanding migraine pathophysiology: from bench to bedside. J Headache Pain. 2019;20:33. DOI: 10.1186/s10194-019-0994-6
Ashina, M., Buse, D. C., Ashina, H., et al. (2021). Migraine: integrated approaches to clinical management and emerging treatments. The Lancet, 397(10283), 1505–1518. https://doi.org/10.1016/S0140-6736(20)32342-4
Aurora SK, Winner PK, Freeman MC, et al. Botulinum toxin in chronic migraine: an update of the literature and practical aspects of management. Headache. 2020
Aurora, S. K., Dodick, D. W., Turkel, C. C., DeGryse, R. E., Silberstein, S. D., Lipton, R. B., ... & PREEMPT 1 Study Group. (2010). OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia, 30(7), 793-803. https://doi.org/10.1177/0333102410364676
Ayata, C., & Lauritzen, M. (2015). Spreading depression, spreading depolarizations, and the cerebral vasculature. Physiological Reviews, 95(3), 953–993. https://doi.org/10.1152/physrev.00027.2014
Bach-Rojecky, L., Lacković, Z. (2013). Botulinum toxin type A and sensory nerves: mechanisms of analgesic action. Pain, 154(9), 1692-1698. https://doi.org/10.1016/j.pain.2013.05.032
Barrett SP, Kunkel D, Engel S, et al. Botulinum toxin for chronic tension-type headache: a randomized, placebo-controlled trial. Cephalalgia. 2019;39(9):1083-1092. https://doi:10.1177/0333102419841151
Bigal, M. E., & Lipton, R. B. (2020). Lifestyle and Migraine. Headache, 60(7), 1269-1279. https://doi.org/10.1111/head.13820
Blumenfeld A, Scher AI, Ziv M, et al. Botulinum toxin A for the prevention of chronic migraine: results from the Phase III REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical program. Headache. 2010;50(2):186-196. https://doi:10.1111/j.1526-4610.2009.01592.x
Blumenfeld A.M., Stark R.J., Freeman M.C., et al. (2018). Long-term efficacy and safety of onabotulinumtoxinA: COMPEL study. J Headache Pain, 19, 13. https://doi.org/10.1186/s10194-018-0840-8
Blumenfeld, A. M., Stark, R. J., Freeman, M. C., et al. (2010). Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. Headache, 58(3), 363–375. https://doi.org/10.1111/head.13205
Bolay, H., Reuter, U., Dunn, A. K., Huang, Z., Boas, D. A., & Moskowitz, M. A. (2002). Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nature Medicine, 8(2), 136–142. https://doi.org/10.1038/nm0202-136
Bruloy E., Sinna R., Grolleau J.L., et al. (2019). Botulinum toxin versus placebo: meta-analysis for migraine prophylaxis. Plast Reconstr Surg, 143(1), 239-250. https://doi.org/10.1097/PRS.0000000000005111
Burch, R. C., Buse, D. C., & Lipton, R. B. (2019). Migraine: epidemiology, burden, and comorbidity. Neurologic Clinics, 37(4), 631–649. https://doi.org/10.1016/j.ncl.2019.06.001
Burstein, R., Noseda, R., Borsook, D. (2015). Migraine: Multiple processes, complex pathophysiology. The Journal of Neuroscience, 35(17), 6619-6629. https://doi.org/10.1523/JNEUROSCI.0373-15.2015
Buse, D. C., Lipton, R. B., Hall, C. B., Tennen, H., & Silberstein, S. D. (2010). Psychological and somatic comorbidities of episodic and chronic migraine. Journal of Neurology, Neurosurgery & Psychiatry, 81(4), 428–432. https://doi.org/10.1136/jnnp.2009.192492
Buse, D. C., Loder, E. W., Gorman, J. A., Stewart, W. F., Reed, M. L., Fanning, K. M., Serrano, D., & Lipton, R. B. (2013). Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache. Headache, 53(8), 1278–1299. https://doi.org/10.1111/head.12150
Cameron, C., Kelly, S., Hsieh, S. C., Murphy, M., Chen, L., Kotb, A., Wells, G. (2015). Triptans in the acute treatment of migraine: a systematic review and network meta‐analysis. Headache: The Journal of Head and Face Pain, 55, 221-235.
Cernuda-Morollón, E., Martínez-Camblor, P., Ramón, C., Pascual, J. (2015). Botulinum toxin type A decreases interictal CGRP plasma levels in patients with chronic migraine. Neurology, 84(7), 731-735. https://doi.org/10.1212/WNL.0000000000001263
Charles, A., & Baca, S. M. (2013). Cortical spreading depression and migraine. Nature Reviews Neurology, 9(11), 637–644. https://doi.org/10.1038/nrneurol.2013.192
Corasaniti M.T., Bagetta G., Nicotera P., et al. (2023). Safety of onabotulinumtoxinA in chronic migraine: systematic review & meta-analysis. Toxins, 15(5), 332. https://doi.org/10.3390/toxins15050332
Derry, C. & Moore, R. A. (2013). Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Review. https://doi.org/10.1002/14651858.CD008039.pub2
Diener H.C., Dodick D.W., Aurora S.K., et al. (2010). OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 2. Cephalalgia, 30(7), 804-814. https://doi.org/10.1177/0333102410364677
Diener, H. C. et al. (2020). Preventive Treatment of Migraine. The Lancet Neurology, 19(7), 596-606. https://doi.org/10.1016/S1474-4422(20)30114-2
Diener, H. C., Charles, A., Goadsby, P. J., Holle, D. (2019). New therapeutic approaches for the prevention and treatment of migraine. The Lancet Neurology, 18(10), 1010-1022. https://doi.org/10.1016/S1474-4422(19)30230-9
Dodick DW, Turkel CC, DeGryse RE, et al. Botulinum toxin type A in the prophylactic treatment of chronic migraine: results of the Phase III REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) studies. Headache. 2010;50(6):1128-1136. https://doi:10.1111/j.1526-4610.2010.01644.x
Dodick, D. W., Turkel, C. C., DeGryse, R. E., Aurora, S. K., Silberstein, S. D., Lipton, R. B., ... & PREEMPT 2 Study Group. (2010). OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Cephalalgia, 30(7), 804-814. https://doi.org/10.1177/0333102410365338
Durham, P. L., Cady, R. K. (2011). Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache, 51(6), 983-997. https://doi.org/10.1111/j.1526-4610.2011.01905.x
Edvinsson, L. (2018). CGRP Antagonists in Migraine Therapy. Neurotherapeutics, 15(3), 628-637. https://doi.org/10.1007/s13311-018-0614-4
Edvinsson, L., & Warfvinge, K. (2013). The trigeminovascular pathway: Role of CGRP and CGRP receptors in migraine. Headache, 57(Suppl 2), 47–55. https://doi.org/10.1111/head.12114
Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain: review of the evidence and clinical recommendations. Lancet Neurol. 2020;19(2).
GBD 2019 Diseases and Injuries Collaborators. (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019. The Lancet, 396(10258), 1204–1222. https://doi.org/10.1016/S0140-6736(20)30925-9
Gelfand AA, Scher AI, Goadsby PJ, et al. Botulinum toxin for the treatment of episodic migraine: a meta-analysis. Neurology. 2020;94(4):150-158. https://doi:10.1212/WNL.0000000000008882
Goadsby PJ, Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. J Headache Pain. 2017;18:1 10. https://doi.org/10.1186/s10194-017-0794-5
Goadsby, P. J. et al. (2020). Targeting CGRP in Migraine: The Monoclonal Antibodies and Gepants. Nature Reviews Neurology, 16(5), 269-282. https://doi.org/10.1038/s41582-020-0331-7
Grazzi L., Montisano D.A., Rizzoli P., et al. (2023). OnabotulinumtoxinA in chronic migraine with MOH: real-world study. Toxins, 15(2), 86. https://doi.org/10.3390/toxins15020086
Hadjikhani, N., Sanchez Del Rio, M., Wu, O., Schwartz, D., Bakker, D., Fischl, B., ... & Moskowitz, M. A. (2001). Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proceedings of the National Academy of Sciences, 98(8), 4687–4692. https://doi.org/10.1073/pnas.071582498
Hansen, J. M., Thomsen, L. L., Olesen, J., & Ashina, M. (2010). Calcitonin gene related peptide triggers migraine like attacks in patients with migraine with aura. Cephalalgia, 30(10), 1179–1186. https://doi.org/10.1177/0333102410368444
Headache Classification Committee of the International Headache Society (IHS) (2018). The International Classification of Headache Disorders, 3rd edition. Cephalalgia, 38(1), 1-211. https://doi.org/10.1177/0333102417738202
Herd C.P., Tomlinson C.L., Rick C., et al. (2019). Botulinum toxins for the prevention of migraine in adults. BMJ Open, 9(7), https://doi.org/10.1136/bmjopen-2018-027953
Houdaille Y, Pannier B, Wilbricht R, et al. Safety of botulinum toxin type A in the prevention of chronic migraine: a systematic review and meta-analysis. Journal of Headache and Pain. 2021;22(1):1-11. https://doi.org/10.1186/s10194-021-01286-3
Iyengar, S., Ossipov, M. H., & Johnson, K. W. (2019). CGRP and the trigeminal system in migraine. Pain, 160(6), 1051–1062. https://doi.org/10.1097/j.pain.0000000000001474
Jackson, J. L. et al. (2019). Amitriptyline for Migraine Prophylaxis: A Meta-Analysis. Headache, 59(9), 1516-1526. https://doi.org/10.1111/head.13523
Karsan, N. & Goadsby, P. J. (2018). Biological insights from the premonitory symptoms of migraine. Nature Reviews Neurology, 14, 699–710. https://doi.org/ 10.1038/s41582 018 0098 4
Laohapiboolrattana, W. et al. (2024). Efficacy of lasmiditan, rimegepant and ubrogepant for acute treatment of migraine in triptan insufficient responders: a systematic review and network meta-analysis. The Journal of Headache and Pain, 25(1), 194. https://doi.org/10.1186/s10194-024-01904-1
Lassen, L. H., Jacobsen, V. B., Haderslev, P. A., Sperling, B., Iversen, H. K., & Olesen, J. (2008). Involvement of calcitonin gene related peptide in migraine: regional cerebral blood flow and blood flow velocity in migraine patients. The Journal of Headache and Pain, 9(3), 151–157. https://doi.org/10.1007/s10194-008-0036-8
Linde, M. et al. (2016). Beta-blockers for the prophylaxis of migraine: a Cochrane review. Cochrane Database of Systematic Reviews, (1), CD003225. https://doi.org/10.1002/14651858.CD003225.pub4
Linde, M., Gustavsson, A., Stovner, L. J., et al. (2012). The cost of headache disorders in Europe: the Eurolight project. European Journal of Neurology, 19(5), 703–711. https://doi.org/10.1111/j.1468-1331.2011.03612.x
Lipton, R. B., Bigal, M. E., Diamond, M., Freitag, F., Reed, M. L., & Stewart, W. F. (2007). Migraine prevalence, disease burden, and the need for preventive therapy. Neurology, 68(5), 343–349. https://doi.org/10.1212/01.wnl.0000252808.97649.21
Lu J., Lu Y., Meng J., et al. (2021). CGRP monoclonal antibodies vs botulinum toxin in chronic migraine: indirect comparison. Front Pharmacol, 12, 631204. https://doi.org/10.3389/fphar.2021.631204
Mahon R., Vo P., Pannagl K., et al. (2023). Relative effectiveness of erenumab vs onabotulinumtoxinA in chronic migraine. Curr Med Res Opin, 39(1), 105-112. https://doi.org/10.1080/03007995.2022.2131299
Matak, I., Bach-Rojecky, L., Filipović, B., Lacković, Z. (2012). Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience, 207, 1-7. https://doi.org/10.1016/j.neuroscience.2012.01.027
Messlinger, K., & Russo, A. F. (2018). Calcitonin gene related peptide and its role in migraine pathogenesis: understanding the mechanisms. Pain, 160(6), 1051–1062. https://doi.org/10.1097/j.pain.0000000000001474
Michael A. Moskowitz (2008). “Defining a Pathway to Discovery from Bench to Bedside: The Trigeminovascular System and Sensitization.” Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526 4610.2008.01110.x
Naradžić, V. et al. (2023). Dihydroergotamine in Migraine Treatment: Efficacy and Tolerability. Journal of Headache and Pain, 24(1), 45. https://doi.org/10.1186/s10194-023-01432-x
Nestoriuc, Y. et al. (2016). Behavioral Treatments for Migraine: A Meta-Analysis. JAMA Internal Medicine, 176(6), 780-789. https://doi.org/10.1001/jamainternmed.2016.0326
Noseda, R., & Burstein, R. (2013). Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain. Pain, 154 Suppl 1, S44–S53. https://doi.org/10.1016/j.pain.2013.07.021
Pringsheim, T. et al. (2012). Preventive Treatment of Migraine: The Canadian Headache Society Guideline. CMAJ, 184(11), 1225-1233. https://doi.org/10.1503/cmaj.112045
Ramachandran, R., Krishnan, P. (2019). Central mechanisms of botulinum toxin in chronic migraine. Expert Review of Neurotherapeutics, 19(10), 959-966. https://doi.org/10.1080/14737175.2019.1651220
Rizzoli, P. et al. (2017). Lifestyle Modifications in Migraine Management. Current Pain and Headache Reports, 21(2), 13. https://doi.org/10.1007/s11916-017-0602-5
Rossi, P. et al. (2015). Medication Overuse Headache: Epidemiology, Diagnosis and Management. Frontiers in Neurology, 6, 102. https://doi.org/10.3389/fneur.2015.00102
Russell, F. A., King, R., Smillie, S.-J., Kodji, X., & Brain, S. D. (2014). Calcitonin gene related peptide: physiology and pathophysiology. Physiological Reviews, 94(4), 1099–1142. https://doi.org/10.1152/physrev.00034.2013
Santoro A., Copetti M., Miscio A.M., et al. (2020). Four-year real-life outcomes of onabotulinumtoxinA in chronic migraine. Neurol Sci, 41, 1809-1820. https://doi.org/10.1007/s10072-020-04283-y
Silberstein, S. D. (2017). Preventive Treatment of Migraine. Neurologic Clinics, 35(2), 225-238. https://doi.org/10.1016/j.ncl.2017.01.007
Silberstein, S. D. et al. (2019). Topiramate and Valproate in Migraine Prevention. Neurology, 92(7), e687–e695. https://doi.org/10.1212/WNL.0000000000006930
Silberstein, S. D., & Lipton, R. B. (2009). Chronic migraine: classification, differential diagnosis, and epidemiology. Headache, 48(1), 7–14. https://doi.org/10.1111/j.1526-4610.2008.01222.x
Stovner, L. J., Nichols, E., Steiner, T. J., Abd Allah, F., Abdelalim, A., Al Raddadi, R. M., ... GBD 2019 Headache Collaborators. (2022). Global, regional, and national burden of migraine and tension-type headache, 1990–2019. The Journal of Headache and Pain, 23(1), 43. https://doi.org/10.1186/s10194-022-01402-2
Stovner, L. J., Nichols, E., Steiner, T. J., Abd-Allah, F., Abdelalim, A., Al-Raddadi, R. M., ... & Vos, T. (2018). Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 17(11), 954-976. https://doi.org/10.1016/S1474-4422(18)30322-3
Stratton, J. A., Goodfellow, N. M., Hirsch, B. M., Bowering, K. J., McKay, C., Eickhoff, J., ... & Staines, W. R. (2016). The effect of botulinum toxin type A on laser evoked potentials in chronic migraine: A randomized controlled trial. Clinical Neurophysiology, 127(1), 433-440. https://doi.org/10.1016/j.clinph.2015.06.025
Togha M, Jafari E, Moosavian A i in. Cranial autonomic symptoms in episodic and chronic migraine: a cross sectional study in Iran. BMC Neurology. 2021;21:493. DOI: 10.1186/s12883-021-02513-0
Wang, J. F., Meng, J., Lawrence, G. W., Zurawski, T. H., Sasse, A., Bodeker, M. A., Gilmore, M. A., Fernández Salas, E., Francis, J., Steward, L. E., Aoki, K. R., & Dolly, J. O. (2008). Novel Chimeras of Botulinum Neurotoxins A and E Unveil Contributions from the Binding, Translocation, and Protease Domains to Their Functional Characteristics. Journal of Biological Chemistry, 283(25), 16993–17002. https://doi.org/10.1074/jbc.M710442200
Woldeamanuel, Y. W., & Cowan, R. P. (2017). Global burden of migraine: current status and future directions. Neurology: Clinical Practice, 7(2), 121–129. https://doi.org/10.1212/CPJ.0000000000000321
Yang, C.-P. et al. (2020). Comparison of new pharmacologic agents with triptans for treatment of migraine. JAMA Network Open.
Zwick, M. et al. (2024). Comparative efficacy and safety of triptans for acute migraine: network meta analysis. The BMJ.
Peroutka SJ. Migraine: a chronic sympathetic nervous system disorder. Headache. 2004;44(1):53–64. https://doi.org/10.1111/j.1526-4610.2004.04011.x
Pietrobon, D., Moskowitz, M. A. (2014). Pathophysiology of migraine. Annual Review of Physiology, 76, 365–391. https://doi.org/10.1146/annurev-physiol-030212-183717
Views:
62
Downloads:
7
Copyright (c) 2025 Marlena Radzka, Michalina Kosowska, Magdalena Barbara Kukulska, Wiktoria Dzierzgowska, Dominika Grzelak, Malwina Draim, Aneta Rostkowska, Sebastian Kupisiak, Natalia Pasierb, Izabela Radzka
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
